Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum
about
The gut hormones in appetite regulationNeuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-αThe novel chemokine receptor, G-protein-coupled receptor 75, is expressed by islets and is coupled to stimulation of insulin secretion and improved glucose homeostasisNovel extrapancreatic effects of incretinDiscovery of gastric inhibitory polypeptide and its subsequent fate: Personal reflectionsPharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populationsAnti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose ControlExploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular DiseaseGLP-1-based strategies: a physiological analysis of differential mode of actionSafety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitusDipeptidyl Aminopeptidase IV from Stenotrophomonas maltophilia Exhibits Activity against a Substrate Containing a 4-Hydroxyproline ResidueDesign and synthesis of 4-(2,4,5-trifluorophenyl)butane-1,3-diamines as dipeptidyl peptidase IV inhibitorsAnagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactionsRegulation of Chemokine Activity - A Focus on the Role of Dipeptidyl Peptidase IV/CD26Mononuclear cells and vascular repair in HHTIdentification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidasePharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjectsInhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberineTruncation of macrophage-derived chemokine by CD26/ dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interactionNovel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonistIdentification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (part I): virtual screening and activity assaysIdentification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (Part II): in silico prediction in antidiabetic extractsAllosteric modulation of the activity of the glucagon-like peptide-1 (GLP-1) metabolite GLP-1 9-36 amide at the GLP-1 receptorDegradation and Stabilization of Peptide Hormones in Human Blood SpecimensStimulation of incretin secretion by dietary lipid: is it dose dependent?Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity.Regulation of appetite to treat obesity.Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs.Development of a robust QSAR model to predict the affinity of pyrrolidine analogs for dipeptidyl peptidase IV (DPP- IV).NMR and alanine scan studies of glucose-dependent insulinotropic polypeptide in water.[Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo.Obesity treatment: novel peripheral targets.GIP and GLP-1, the two incretin hormones: Similarities and differencesEncapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus.Partial D-amino acid substitution: Improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptideAssessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials.European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS).Obesity pharmacotherapy: what is next?Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous systemInhibitory potential of Turbinaria ornata against key metabolic enzymes linked to diabetes.
P2860
Q21296779-DB217844-50F6-41BB-A40F-C15F47ECD97CQ24292941-0FD7FE4F-60A9-4EF2-81FB-769B2897A682Q24319758-02E57998-FEE1-445B-855D-59F71F587E0FQ26749181-43F1AC03-E855-4046-B987-67CB91DC5074Q26749226-FA46CF20-D058-48B4-A711-159B0F99F387Q26749524-39359D1C-F6DB-486C-8EC9-911325230169Q26750746-E0A3C297-CD17-47B6-8FBA-456C7A5CF1DEQ26801173-1912439E-5A1B-4703-8EDF-B1AC30713686Q26997149-AB597847-F961-4F78-9A09-01AB91A1996DQ27027877-7EA642E0-9869-4F89-AC6F-3A69F7EA5E9CQ27652311-529B2389-0186-4608-A44D-3663C9642E9FQ27684616-AB4F5A87-0BE2-49D3-B7D1-9A206DC6ECC9Q27701492-A9F4FA08-E778-422D-920D-46665E1E01C4Q28072580-9905C5A9-1D67-4D46-A0E1-7E8D34315112Q28084374-30C3B13B-D46A-4B6D-A76A-2A7DF181434AQ28147264-6798C216-823E-4756-8305-BF5EFD96BFC7Q28252893-075460FB-A862-42DE-9D08-B3CF59E593CFQ28253310-BABE9C7A-7659-4A6E-BC90-B1924ADB612CQ28296438-0409AD1E-426F-46A0-967E-57F20B9EC0F3Q28475510-B398FDC3-11C4-4ED3-B388-5C48CD50C53CQ28483681-9BDE28B6-4E55-4D10-B2CA-6DD19A08B82CQ28483936-22582C6A-DEC7-4757-9BB6-DE4AA1AF4BDFQ28484498-90FC226A-73E2-4A74-993A-26367FE5D1B2Q28546842-956637CA-4C93-45A2-A980-2BD6D411C664Q28572504-729F42BD-B0EA-4707-963E-FB48858DC5E0Q30399390-7AC98BD6-A0B4-4613-8EE6-D206E29BDE2CQ30403705-32B5E758-5E0A-411E-8934-CCC1AD3CF04BQ30652020-10F31A0D-2A37-4AE9-84D5-A0E1F9009B88Q30998308-23496295-C9E6-41E7-9885-AAC57D227281Q31036989-A86E9073-9742-4903-892B-E0EFCE4E1411Q33194892-1F359D17-2201-4C8F-92B3-BBF52C302FFEQ33607971-B512CBE0-E6D6-47D2-B710-0F136B11B77CQ33609502-5E02953A-D3B1-4E97-B3F9-00AAF6C59B24Q33692584-B1C0FDCD-6BE0-4C38-825F-E825D672007FQ33723283-9E6CFA0D-C03B-4CA9-8D51-B1A2D9412F4BQ33732627-3D2ADAFD-D9C5-48AE-8D81-26630FA70038Q33761211-8B1CFCED-A822-4658-BAEF-D001D55F836CQ33827988-7B798215-A5C8-4CB9-9AF7-080D59C5503BQ33840311-408051A5-EF20-4A7B-83FE-A6EB30E5665FQ33890749-3AB869B4-5933-484C-A8AC-34AF5DA3578A
P2860
Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum
description
1993 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հունիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1993
@ast
im Juni 1993 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1993/06/15)
@sk
vědecký článek publikovaný v roce 1993
@cs
wetenschappelijk artikel (gepubliceerd op 1993/06/15)
@nl
наукова стаття, опублікована в червні 1993
@uk
مقالة علمية (نشرت في 15-6-1993)
@ar
name
Dipeptidyl-peptidase IV hydrol ...... eir degradation in human serum
@ast
Dipeptidyl-peptidase IV hydrol ...... eir degradation in human serum
@en
Dipeptidyl-peptidase IV hydrol ...... eir degradation in human serum
@nl
type
label
Dipeptidyl-peptidase IV hydrol ...... eir degradation in human serum
@ast
Dipeptidyl-peptidase IV hydrol ...... eir degradation in human serum
@en
Dipeptidyl-peptidase IV hydrol ...... eir degradation in human serum
@nl
prefLabel
Dipeptidyl-peptidase IV hydrol ...... eir degradation in human serum
@ast
Dipeptidyl-peptidase IV hydrol ...... eir degradation in human serum
@en
Dipeptidyl-peptidase IV hydrol ...... eir degradation in human serum
@nl
P2093
P2860
P3181
P1433
P1476
Dipeptidyl-peptidase IV hydrol ...... eir degradation in human serum
@en
P2093
B. Gallwitz
R. Mentlein
W. E. Schmidt
P2860
P304
P3181
P356
10.1111/J.1432-1033.1993.TB17986.X
P407
P577
1993-06-15T00:00:00Z